Rein Therapeutics Receives Nasdaq Delisting Notice over $1 Bid Rule

What Happened
Rein Therapeutics, Inc. (RNTX) announced in an 8‑K that on August 21, 2026 it received a notice from The Nasdaq Stock Market stating the company is not in compliance with Nasdaq Listing Rule 5550(a)(1) because the closing bid price of its common stock was below $1.00 over a 30 consecutive trading‑day period. Under Nasdaq Rule 5810(c)(3)(A), the company has 180 days from the notice date—until February 17, 2027—to regain compliance by achieving a closing bid of at least $1.00 per share for a minimum of 10 consecutive business days.

Key Details

• Notice received: August 21, 2026.
• Compliance issue: closing bid price below $1.00 over the prior 30 consecutive trading days (Rule 5550(a)(1)).
• Cure period: 180 days from the notice (deadline February 17, 2027) to achieve a $1.00+ closing bid for at least 10 consecutive business days.
• If not regained: Nasdaq may start suspension and delisting procedures; company may be eligible for additional time only if it meets other Nasdaq Capital Market initial listing standards (except the bid price) and provides required undertakings.

Why It Matters
A Nasdaq delisting could limit liquidity and trading options for RNTX shares and may affect investor confidence. The company has a defined window to regain compliance; investors should watch the stock’s closing price relative to the $1.00 threshold and any updates from Rein Therapeutics about actions to regain compliance or requests for additional time from Nasdaq. This 8‑K is a mandatory disclosure of the listing risk—not a final delisting decision.